Mazziotta, F., Martin, L. E., Egan, D. N., Bar, M., Kinsella, S., Paulson, K. G., . . . Chapuis, A. G. (2025). A phase I/II trial of WT1-specific TCR gene therapy for patients with acute myeloid leukemia and active disease post-allogeneic hematopoietic cell transplantation: Skewing towards NK-like phenotype impairs T cell function and persistence. Nature communications, 16(1), 5214-20. https://doi.org/10.1038/s41467-025-60394-0
Citace podle Chicago (17th ed.)Mazziotta, Francesco, et al. "A Phase I/II Trial of WT1-specific TCR Gene Therapy for Patients with Acute Myeloid Leukemia and Active Disease Post-allogeneic Hematopoietic Cell Transplantation: Skewing Towards NK-like Phenotype Impairs T Cell Function and Persistence." Nature Communications 16, no. 1 (2025): 5214-20. https://doi.org/10.1038/s41467-025-60394-0.
Citace podle MLA (9th ed.)Mazziotta, Francesco, et al. "A Phase I/II Trial of WT1-specific TCR Gene Therapy for Patients with Acute Myeloid Leukemia and Active Disease Post-allogeneic Hematopoietic Cell Transplantation: Skewing Towards NK-like Phenotype Impairs T Cell Function and Persistence." Nature Communications, vol. 16, no. 1, 2025, pp. 5214-20, https://doi.org/10.1038/s41467-025-60394-0.